Explore the words cloud of the COMBINE project. It provides you a very rough idea of what is the project "COMBINE" about.
The following table provides information about the project.
|Coordinator Country||Sweden [SE]|
|Total cost||25˙460˙100 €|
|EC max contribution||8˙000˙000 € (31%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-11-01 to 2025-10-31|
Take a look of project's partnership.
|1||UPPSALA UNIVERSITET||SE (UPPSALA)||coordinator||3˙063˙260.00|
|2||BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL||DE (LANGEN)||participant||1˙466˙860.00|
|3||GRITSYSTEMS AS||DK (VALBY)||participant||800˙625.00|
|4||FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.||DE (MUNCHEN)||participant||800˙000.00|
|5||STATENS SERUM INSTITUT||DK (KOBENHAVN S)||participant||685˙000.00|
|7||ASCLEPIA OUTSOURCING SOLUTIONS BVBA||BE (DESTELBERGEN)||participant||461˙250.00|
|8||BEAM ALLIANCE||FR (PARIS)||participant||104˙255.00|
|9||EVOTEC INTERNATIONAL GMBH||DE (HAMBURG)||participant||0.00|
|10||GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.||UK (BRENTFORD)||participant||0.00|
|11||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
The loss of antibiotic effectiveness due to increasing antimicrobial resistance (AMR) is a serious threat to global public health. The IMI2 AMR Accelerator will develop new agents to treat and prevent infections caused by MDR and XDR bacteria, including Mycobacterium tuberculosis and non-tuberculous mycobacteria. The COMBINE proposal addresses Pillar A, the Capability Building Network (CBN) of the AMR Accelerator programme.
The COMBINE consortium will form a Coordination and Support Office (CSO) that will support the delivery of projects across the AMR Accelerator, as well as with efficient communication among projects of the Accelerator and within the AMR community. In addition, we will establish an IT infrastructure that will allow for the FAIRification, collection, aggregation, storage, sharing, and analysis of vaccine and antibacterial preclinical and clinical data sets. When setting up the CSO, we will build on learnings from the two IMI ND4BB projects: ENABLE (an antibacterial discovery and development engine) and TRANSLOCATION (which has built an information centre for data sharing).
COMBINE partners will work to accelerate scientific discoveries in the AMR field by optimisation and standardisation of animal infection models, and development of improved models for translation of preclinical animal efficacy data and statistical analysis of clinical data. This will set new standards for the translational and predictive relevance of preclinical data and facilitate optimized design for new clinical trials. Results will feed into study and trial design throughout the AMR Accelerator to achieve more stringent and reliable development programmes.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COMBINE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "COMBINE" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Bringing a prophylactic Ebola vaccine to licensureRead More
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.Read More